+++ Ihre Meinung ist uns wichtig: Wie zufrieden sind Sie mit finanzen.ch? - Hier an unserer Umfrage teilnehmen! +++ -w-
<
News + Analysen
News + Adhoc
Analysen
Kursziele
>
<
Unternehmen
Termine
Profil
>
<
zugeh. Wertpapiere
Strukturierte Produkte
>
15.02.2019 13:39:06

The Daily Biotech Pulse: Acorda Swings To Profit, Achaogen Offering, Bioblast Strikes Sanfilippo Syndrome Deal

Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks(Biotech stocks hitting 52-week highs on Feb. 14)argenx SE – ADR (NASDAQ: ARGX)Orthofix Medical Inc (NASDAQ: OFIX)OUTLOOK THERAPEUTICS, INC. (NASDAQ: OTLK)(reported a narrower net loss per share for fiscal-year first-quarter)Vericel Corp (NASDAQ: VCEL)Wright Medical Group NV (NASDAQ: WMGI)Down In The Dumps(Biotech stocks hitting 52-week lows on Feb. 14)CELLECT BIOTECH/S ADR (NASDAQ: APOP)Endologix, Inc. (NASDAQ: ELGX)MediciNova, Inc. (NASDAQ: MNOV)MOTIF BIO PLC/S ADR (NASDAQ: MTFB)(received complete response letter for its NDA for iclaprim for treating acute bacterial skin and skin structure infections)Organogenesis Holdings Inc (NASDAQ: ORGO)Ovid Therapeutics Inc (NASDAQ: OVID)Scpharmaceuticals Inc (NASDAQ: SCPH)Xeris Pharmaceuticals Inc (NASDAQ: XERS)(priced its common stock offering)Stock In FocusAcorda Posts an Unexpected Profit For Q4Acorda Therapeutics Inc (NASDAQ: ACOR) reported fourth-quarter revenues of $69.152 million compared to $188.398 million in the year-ago period. The sharp decline was due to the loss of exclusivity for its Ampyra, as generics entered the market. Non-GAAP net income fell from 61 cents per share to 45 cents per share.The stock rallied 9.25 percent to $17 in after-hours trading.Bioblast Strikes Partnership For Developing Rare Disease DrugIsraeli biotech Bioblast Pharma Ltd (NASDAQ: ORPN) announced a clinical collaboration with Team Sanfilippo, a non-profit medical research foundation, to evaluate the safety and efficacy of Bioblast's proprietary Trehalose solution for treating patients with Sanfilippo syndrome.Under the terms of the deal, the foundation will conduct an open-label study in up to 20 Sanfilippo patients to evaluate the safety ...Full story available on Benzinga.com
Weiter zum vollständigen Artikel bei "Benzinga"

Analysen zu Biotech Holdings LtdShsmehr Analysen

Eintrag hinzufügen

SMI im Aufwind – Saudi Aramco vor IPO | BX Swiss TV

Aktien in diesem Artikel

Achaogen Inc 0.01 4.84% Achaogen Inc

Finanzen.net News

pagehit
FinanzenNet.Finando.Web.Core.Areas.Article.ViewModels.News.DetailsViewModel FinanzenNet.Finando.Web.Core.Extensions.VueComponent ;